AU2008296948A1 - Improved brimonidine compositions for treating erythema - Google Patents

Improved brimonidine compositions for treating erythema Download PDF

Info

Publication number
AU2008296948A1
AU2008296948A1 AU2008296948A AU2008296948A AU2008296948A1 AU 2008296948 A1 AU2008296948 A1 AU 2008296948A1 AU 2008296948 A AU2008296948 A AU 2008296948A AU 2008296948 A AU2008296948 A AU 2008296948A AU 2008296948 A1 AU2008296948 A1 AU 2008296948A1
Authority
AU
Australia
Prior art keywords
composition according
gel
weight
percent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008296948A
Other languages
English (en)
Inventor
Christopher V. Powala
Klaus Theobald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Laboratories LP
Original Assignee
Galderma Laboratories LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Laboratories LP filed Critical Galderma Laboratories LP
Publication of AU2008296948A1 publication Critical patent/AU2008296948A1/en
Assigned to GALDERMA LABORATORIES INC. reassignment GALDERMA LABORATORIES INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: GALDERMA LABORATORIES L.P.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008296948A 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema Abandoned AU2008296948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
US60/967,191 2007-08-31
PCT/US2008/010290 WO2009032223A1 (en) 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema

Publications (1)

Publication Number Publication Date
AU2008296948A1 true AU2008296948A1 (en) 2009-03-12

Family

ID=40407909

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008296948A Abandoned AU2008296948A1 (en) 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema

Country Status (12)

Country Link
US (3) US20090061020A1 (enExample)
EP (1) EP2200617A4 (enExample)
JP (1) JP2010537988A (enExample)
KR (1) KR20100055453A (enExample)
CN (2) CN101808645A (enExample)
AR (1) AR068816A1 (enExample)
AU (1) AU2008296948A1 (enExample)
BR (1) BRPI0816097A2 (enExample)
CA (1) CA2698680A1 (enExample)
MX (1) MX2010002392A (enExample)
NO (1) NO20100301L (enExample)
WO (1) WO2009032223A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
WO2010136594A2 (en) * 2009-05-29 2010-12-02 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
EP2493309A4 (en) * 2009-10-26 2013-05-01 Galderma Pharma Sa METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
RU2535008C2 (ru) 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
MX2012010824A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
SG189896A1 (en) 2010-10-21 2013-06-28 Galderma Sa Brimonidine gel compositions and methods of use
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
CA2814975A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel composition
AU2012217858A1 (en) 2011-02-15 2013-09-05 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
BR112014009210A2 (pt) 2011-10-19 2017-04-18 Galderma Sa método para a redução da vermelhidão facial cutânea
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
WO2015191917A1 (en) 2014-06-11 2015-12-17 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
WO2019014518A1 (en) * 2017-07-14 2019-01-17 Galderma Research And Development METHODS AND COMPOSITIONS FOR REDUCING ADVERSE EFFECTS OF CHEMOTHERAPEUTIC TREATMENTS
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
EP2230910A4 (en) * 2007-12-21 2011-04-13 Galderma Lab Inc PRE-SURGICAL TREATMENT

Also Published As

Publication number Publication date
BRPI0816097A2 (pt) 2016-11-01
US20120040016A1 (en) 2012-02-16
CN102552112A (zh) 2012-07-11
AR068816A1 (es) 2009-12-09
CN101808645A (zh) 2010-08-18
KR20100055453A (ko) 2010-05-26
JP2010537988A (ja) 2010-12-09
US20120282346A1 (en) 2012-11-08
EP2200617A1 (en) 2010-06-30
NO20100301L (no) 2010-03-25
WO2009032223A1 (en) 2009-03-12
MX2010002392A (es) 2010-07-28
EP2200617A4 (en) 2011-01-12
US20090061020A1 (en) 2009-03-05
CA2698680A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
US20120282346A1 (en) Brimonidine compositions for treating erythema
EP2481412B1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
DK2552449T3 (en) COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
RU2587041C2 (ru) Способ предотвращения или лечения опухоли кожи
US20110224215A1 (en) Pre-surgical treatment
JP2010537988A5 (enExample)
JP2016525553A (ja) 皮膚肥厚の治療法
US9744168B2 (en) Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
KR20140091544A (ko) 모세혈관종 치료방법
HK1180208A (en) Compositions comprising brimonidine for the treatment of erythema
HK1180208B (en) Compositions comprising brimonidine for the treatment of erythema

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application